deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT05028751

A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination With the FLT3 Inhibitor Gilteritinib, in Patients With FLT3-mutated Relapsed or Refractory AML

Sponsor: Kronos Bio

Updated 20 times since 2021 Last updated: Jul 11, 2024 Started: Aug 5, 2022 Primary completion: Apr 9, 2024 Completion: Apr 9, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision

A PHASE1/PHASE2 clinical study on Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia, this trial is terminated or withdrawn. The trial is conducted by Kronos Bio and has accumulated 20 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Jun 2022 · 3 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Jan 2024 · 4 months · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

20 versions recorded
  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2PHASE1/PHASE2

  3. May 2024 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not RecruitingTerminated

  4. Mar 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jan 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: RecruitingActive Not Recruiting

Show 15 earlier versions
  1. Sep 2023 — Jan 2024 [monthly]

    Recruiting PHASE1_PHASE2

  2. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jun 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jan 2023 — Apr 2023 [monthly]

    Recruiting PHASE1_PHASE2

  7. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE1_PHASE2

  8. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE1_PHASE2

  9. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  11. Mar 2022 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

  12. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet RecruitingRecruiting

  14. Dec 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  15. Sep 2021 — Dec 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kronos Bio
Data source: Kronos Bio

For direct contact, visit the study record on ClinicalTrials.gov .